

ID	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Comments	Reasons for delay correspond to:	
1	19YH/0400	271539	A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal, Parallel Group Study of Patromer for the Management of Hyperkalemia in Subjects Receiving Renin-Angiotensin-Aldosterone System Inhibitor (RAAS) Medications for the Treatment of Heart Failure (DIAMOND)	No		176			29/01/2020	29/01/2020	09/01/2020	25/06/2020	23/07/2020		A - Permissions delayed/denied D - Sponsor Delays	Screening going on, No Suitable patients , Sponsor permission delay	Sponsor	
2	19LO/0738	258589	A randomised, two-arm (1:1 ratio), double blind, placebo controlled phase III trial to assess the efficacy, safety, cost and cost-effectiveness of rituximab in treating de novo or relapsing NS in patients with MCD/FSGS (TURING)	No		21			28/10/2019	07/02/2020	14/06/2019		28/02/2020		F - No patients seen	Recruitment on hold - COVID-19 .	Neither	
3	17/SC/0039	220282	A randomised, double-blind, multicentre, placebo controlled study to evaluate the safety and efficacy of methoxyflurane (PENTHROX <sup>7</sup> ) for the treatment of acute pain in children and adolescents from 6 to less than 18 years of age (presenting to an Emergency Department with minor trauma)	No		240			21/10/2019	12/02/2020	18/04/2017	26/08/2020	09/10/2020		A - Permissions delayed/denied D - Sponsor Delays F - No patients seen	Screening going on, No Suitable patients , Sponsor permission delay	Sponsor	
4	19/EE/0327	270157	A 12-week randomized controlled trial to compare TOUJEO <sup>7</sup> and TRESIBA <sup>7</sup> in terms of glucose values in target range and variability during continuous glucose monitoring in patients with type 1 diabetes mellitus	Yes	29/03/2021	213	171	384	22/10/2019	10/03/2020	13/02/2020	28/09/2020	09/10/2020		A - Permissions delayed/denied D - Sponsor Delays F - No patients seen	Screening going on, No Suitable patients , Sponsor permission delay	Sponsor	
5	18/SC/0472	234266	Efficacy of propofol-supplemented cardioplegia on biomarkers of organ injury in patients having cardiac surgery using cardiopulmonary bypass: Propofol cardioplegia for myocardial protection	No		14			28/05/2019	14/02/2020	24/10/2018	11/02/2020	28/02/2020	26/11/2020	F - No patients seen	Screening going on, No Suitable patients ,	Neither	
6	19/EM/0334	257450	A Single Centre, Open-label, Single-group Exploratory Pilot Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients with Immunoglobulin A Nephropathy	Yes	06/01/2021	275	89	364	29/11/2019	08/01/2020	07/01/2020	01/09/2020	09/10/2020	19/10/2020		A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor
7	19WM/0308	268333	Exercise as an anti-inflammatory treatment in axial spondyloarthritis (axSpA): a proof of concept study	No					17/06/2019	30/03/2020	29/10/2019		02/02/2021		A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor	
8	19/EM/0282	242364	A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS 7 IGAN)	Yes	06/04/2021	260	147	407	27/08/2019	24/02/2020	06/12/2019	29/04/2020	10/11/2020	20/11/2020		A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor
9	19LO/1921	271139	A Phase 1, Randomized, Dose and Schedule Evaluation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Belantamab Mafodotin Administered in Combination with Standard of Care in Participants with Newly Diagnosed Multiple Myeloma	Yes	07/12/2020	34	272	306	15/08/2019	05/02/2020	03/02/2020	25/02/2020	10/03/2020	29/10/2020		F - No patients seen	Screening going on, No Suitable patients ,	Neither
10	20YH/0177	273999	The effect of increased sodium intake with a carbohydrate-rich meal on glucose homeostasis in subjects without diabetes after bariatric surgery.	No					06/02/2020	07/05/2020	29/06/2020				A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor	
11	20/SC/0153	271051	Adalimumab vs placebo as add-on to Standard Therapy for autoimmune Uveitis: Tolerability, Effectiveness and cost-effectiveness: a randomized controlled trial.	No					24/03/2020	12/05/2020	26/10/2020				A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor	
12	19WS/0188	270378	Aldose Reductase Inhibition for Stabilization of Exercise capacity in Heart Failure (ARISE-HF: A Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ATR-001 in Patients with Diabetic Cardiomyopathy / Stage B Heart Failure at High Risk of Progression to Overt Heart Failure (Stage C Heart Failure)	No		223			05/03/2020	05/03/2020	14/02/2020	22/09/2020	14/10/2020	14/10/2020		A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor
13	18/SC/0580	235355	FROSTTIE: A randomised controlled trial of Frenotomy and breastfeeding support Or breastfeeding Support without frenotomy to investigate continuation of breastfeeding for babies with Tongue-TIE	No		157			19/02/2020	02/06/2020	19/12/2018	27/08/2020	06/11/2020		A - Permissions delayed/denied C - Closed by sponsor	Study abandoned by sponsor . Sponsor permission delay	Sponsor	
14	20YH/0123	263968	The effect of Canagliflozin 300mg in subjects without diabetes after bariatric surgery, on glucose homeostasis (CONTROL): A proof-of-concept, randomised, open-label, two period crossover study.	No					11/09/2019	04/06/2020	01/06/2020	19/03/2021			A - Permissions delayed/denied	Sponsor permission delay	Sponsor	
15	20WM/0117	276905	Impact of exercise training in combination with dapagliflozin on physical function in adults with type 2 diabetes mellitus: a randomised controlled trial	No					29/01/2020	10/06/2020	02/06/2020	01/09/2020			A - Permissions delayed/denied	Sponsor permission delay	Sponsor	
16	18/EE/0275	229033	A randomized, double blind, controlled mechanistic study of rituximab and belimumab combination therapy in PR3 ANCA-associated vasculitis	Yes	23/09/2020	26	203	229	27/05/2019	07/02/2020	04/12/2018	25/02/2020	04/03/2020	25/08/2020		F - No patients seen	Screening going on, No Suitable patients ,	Neither
17	19/EE/0286	255237	A Randomised Controlled Trial of Mepolizumab Initiated During Admission to Hospital for a Severe Exacerbation of Eosinophilic COPD	Yes	02/09/2020	10	201	211	13/09/2019	04/02/2020	12/12/2019	11/02/2020	14/02/2020	13/08/2020		F - No patients seen	Screening going on, No Suitable patients ,	Neither

ID	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Comments	Reasons for delay correspond to:
18	19NE/0110	257719	A randomised, double-blind, placebo-controlled, cross-over trial of zibotentan in microvascular angina	Yes	17/11/2020	188	70	258	07/10/2019	04/03/2020	04/12/2019	28/08/2020	08/09/2020	08/08/2020	A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor
19	20EM/0003	269023	Multicentre open label, pragmatic randomised controlled trial of early surfactant therapy versus expectant management in late preterm and early term infants with respiratory distress	Yes	03/09/2020	112	70	182	27/09/2019	05/03/2020	14/02/2020	12/06/2020	25/06/2020	02/09/2020	A - Permissions delayed/denied D - Sponsor Delays F - No patients seen	Screening going on, No Suitable patients , Sponsor permission delay	Sponsor
20	18NW/0031	230387	A multi-centre, randomised, parallel group, open-label, phase II, single-stage selection trial of nanoliposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (NEC)	No		135			10/03/2018	04/03/2020	08/02/2018	03/03/2020	17/07/2020	17/08/2020	A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor
21	19SC/0566	265559	Weight Bearing in Ankle Fractures. A randomised clinical trial of weight-bearing following operatively treated ankle fracture.	Yes	02/09/2020	164	30	194	21/02/2020	21/02/2020	02/12/2019	30/06/2020	03/08/2020	03/08/2020	A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor
22	18NW/0765	250220	Testing a novel aid to diagnosis of peritonitis in clinic	Yes	05/07/2020	0	146	146	21/08/2018	10/02/2020	01/04/2019	07/02/2020	10/02/2020	03/07/2020	F - No patients seen	Screening going on, No Suitable patients ,	Neither
23	19WM/0364	257918	Letrozole or Clomifene, with or without metformin, for ovulation induction in women with polycystic ovary syndrome: a 2x2 factorial design randomised trial (The LOCI trial)	No					24/02/2020	14/08/2020	09/06/2020				A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor
24	20WS/0062	256875	A multicomponent physical activity programme for women who have been treated for cervical cancer: A feasibility study	Yes	28/10/2020	123	23	146	20/05/2020	04/06/2020	20/05/2020	06/08/2020	05/10/2020	21/10/2020	A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor
25	19EM/0361	270469	A Phase 1b Open-label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Binilumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma	No		20			19/08/2019	06/08/2020	14/02/2020	26/08/2020	26/08/2020	08/12/2020	F - No patients seen	Screening going on, No Suitable patients ,	Neither
26	20EM/0162	280970	Randomized, double blind, placebo controlled study to evaluate the effect of dupilumab on airway inflammation through assessments of lung function, mucus plugging and other lung imaging parameters in patients with asthma	No					09/09/2020	09/09/2020	28/10/2020	19/04/2021			A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor
27	20YH/0232	280105	ATNECT?Adjuvant management in T1-3N1M0 breast cancer patients with FNA or core biopsy proven nodal metastases at presentation who convert to node negative after NeoAdjuvant Chemotherapy	No					09/03/2020	18/09/2020	22/10/2020	24/04/2021			A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor
28	18WA/0239	243333	Determining the Effectiveness of early Intensive Versus Escalation approaches for the treatment of Relapsing-Remitting Multiple Sclerosis (DELIVER-MS)	No		68			05/03/2020	23/09/2020	21/12/2018	16/11/2020	30/11/2020		A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor
29	19YH/0380	273434	A Phase 1, Open-label, Single-dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Ceftazidime Avibactam (CAZ-AVI) in Children From 3 Months to Less Than 18 Years of Age Who are Hospitalized and Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Nosocomial Pneumonia, Including Ventilator-Associated Pneumonia	No		44			01/04/2019	23/09/2020	25/02/2020	25/09/2020	06/11/2020		A - Permissions delayed/denied D - Sponsor Delays F - No patients seen	Screening going on, No Suitable patients , Sponsor permission delay	Sponsor
30	19WM/0251	264348	Randomised phase IIIb study of Rituximab and Ibrutinib (RI) versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as initial therapy for Waldenström's macroglobulinaemia	Yes	12/04/2021	9	178	187	01/08/2019	07/10/2020	07/11/2019	19/11/2020	16/10/2020		F - No patients seen	Screening going on, No Suitable patients ,	Neither
31	20EE/0031	275993	Randomized, placebo controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate efficacy and safety of BAY 2433334 in patients following an acute non-cardioembolic ischemic stroke	No		77			20/12/2019	11/08/2020	03/04/2020	09/09/2020	27/10/2020	02/11/2020	A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor
32	19SC/0416	269256	A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MED8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-risk Children (MEDLEY)	Yes	08/10/2020	42	45	87	16/04/2020	13/07/2020	04/10/2019	11/08/2020	24/08/2020	01/10/2020	D - Sponsor Delays F - No patients seen	Screening going on, No Suitable patients , Sponsor permission delay	Sponsor
33	17LO/0054	199080	Prospective randomised trial of digital breast tomosynthesis (DBT) plus standard 2D digital mammography (2DM) or synthetic 2D mammography (S 2D) compared to standard 2D digital mammography in breast cancer screening.	No					15/10/2020	15/10/2020	13/02/2017				A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor

ID	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Comments	Reasons for delay correspond to:
34	19/NW/0135	252254	An International Randomised Clinical Trial of Therapeutic Interventions with the Potential to Improve Outcome in Adults with Acute Myeloid Leukaemia and High Risk Myelodysplasia Undergoing Allogeneic Stem Cell Transplantation	Yes	28/04/2021	61	210	271	01/07/2019	31/07/2020	17/05/2019	02/10/2020	30/09/2020	12/10/2020	A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor
35	19/LO/0408	257662	PROMISE UK Percutaneous Deep Vein Arterialization with the Limflow System	No					10/09/2020	22/10/2020	03/05/2019	08/03/2021			A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor
36	20/SS/0057	281986	STOP-COVID19	Yes	13/07/2020	38	31	69	05/05/2020	05/05/2020	22/05/2020	05/06/2020	12/06/2020	09/07/2020			
37	19/SC/0634	252084	Treating severe paediatric asthma: a randomised controlled trial of mepolizumab and omalizumab (TREAT trial)	No					23/01/2020	28/10/2020	04/08/2020				A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor
38	20/ES/0031	276439	Protocol 18F-MC-GPGN The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes (SURPASS-CVOT)	Yes	18/11/2020	53	23	76	17/02/2020	03/09/2020	30/09/2020	21/10/2020	28/10/2020	05/11/2020	A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor
39	20/NW/0169	278290	Nasal High-Flow Oxygen Therapy After Cardiac Surgery (NOTACS) Study: Effect of High-Flow Nasal Therapy on Patient-Centred Outcomes in Patients at High Risk of Postoperative Pulmonary Complications After Cardiac Surgery: A Multicentre Randomised Controlled Trial.	No					26/03/2020	30/10/2020	19/06/2020				A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor
40	20/NI/0131	278283	A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS CABOZANTINIB ALONE IN PATIENTS WITH INOPERABLE, LOCALLY ADVANCED, OR METASTATIC RENAL CELL CARCINOMA WHO EXPERIENCED RADIOGRAPHIC TUMOR PROGRESSION DURING OR AFTER IMMUNE CHECKPOINT INHIBITOR TREATMENT	No		23			13/08/2020	25/11/2020	21/10/2020	07/12/2020	18/12/2020				
41	19/LO/0966	262945	A Phase 3, Randomised, Double-Blind, Multinational, Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab (PRV-031), a Humanised, FcR Non-Binding, anti-CD3 Monoclonal Antibody, in Children and Adolescents with Newly Diagnosed Type 1 Diabetes Mellitus	No		2			05/08/2019	04/02/2020	26/07/2019	05/11/2019	06/02/2020	11/03/2020			
42	20/SC/0433	282917	Wrist Injury Strengthening Exercise: a randomised multicentre feasibility study of resistance exercise versus usual care for optimising function after distal radius fracture in adults aged 50 years or over	No					30/10/2020	26/11/2020	05/01/2020						
43	19/EE/0174	255746	The third Multi-Centre Intra-Pleural Sepsis Trial (MST-3): Early Video-Assisted Thoroscopic Surgery (VATS) or Intra-Pleural Enzyme Therapy (IET) in Pleural Infection - a feasibility, randomised trial	Yes	04/12/2020	33	38	71	24/09/2020	24/09/2020	30/07/2019	23/10/2020	27/10/2020	27/10/2020			
44	20/LO/0639	281304	A Phase 2a, Open-label, Single-arm, 2-Part Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-147 in Adults With APO1-mediated Focal Segmental Glomerulosclerosis.	Yes	13/04/2021	33	112	145	05/11/2019	19/11/2020	01/06/2020	21/12/2020	22/12/2020	22/12/2020			
45	18/SC/0634	233709	SYNELLAR: A phase II, randomised study of CHOP-R in combination with acalabrutinib compared to CHOP-R in patients with newly diagnosed Richter's Syndrome (RS) and a placebo for initial investigations into activity of novel treatments in relapsed/refractory and	Yes	08/09/2020	20	19	39	02/08/2019	31/07/2020	31/01/2019	06/08/2020	20/08/2020	02/09/2020			
46	20/EM/0068	274507	Daily intake of Lactobacillus casei Shirota (LCS) modulates intestinal permeability and decreases circulating levels of endotoxin that associate with both cardiovascular and all-cause mortality in haemodialysis (HD) patients.	Yes	28/10/2020	20	44	64	18/12/2019	25/08/2020	03/04/2020	03/09/2020	14/09/2020	21/09/2020			
47	20/SC/0189	278270	A phase III, open-label, randomised study of osimertinib with or without platinum plus pemterex chemotherapy, as first-line treatment in patients with epidermal growth factor receptor (EGFR) mutation-positive, locally advanced or metastatic non-small cell lung cancer	Yes	08/12/2020	16	26	42	27/10/2020	27/10/2020	10/07/2020	29/10/2020	12/11/2020	20/11/2020			
48	20/NE/0092	277972	PHARMACOKINETICS AND PRELIMINARY ANTITUMOR ACTIVITY OF RO7227166 (A CD19 TARGETED 4-1BB LIGAND) IN COMBINATION WITH OBINITUZUMAB AND	Yes	25/08/2020	22	26	48	06/03/2020	08/07/2020	05/05/2020	27/07/2020	30/07/2020	30/07/2020			
49	19/EE/0362	272768	A Randomised Multiple Centre Trial of Conservative versus Liberal Oxygenation Targets in Critically Ill Children (Oxy-PICU)	Yes	16/10/2020	21	31	52	11/08/2020	25/08/2020	23/12/2019	04/09/2020	15/09/2020	15/09/2020			
50	20/NE/0171	279531	A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB AND TIRAGOLUMAB COMPARED WITH DURVALUMAB IN PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE	No					01/12/2020	10/12/2020	04/09/2020	18/12/2020					
51	20/NW/0183	1003230	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SNF472 When added to Background Care for the Treatment of Calciphylaxis.	No		11			29/01/2020	10/12/2020	21/05/2020	15/12/2020	21/12/2020				

ID	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Comments	Reasons for delay correspond to:
52	19/NE/0215	234453	Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma: A phase III trial to compare standard and frailty-adjusted induction therapy with isatuximab, lenalidomide and dexamethasone (IDe) and maintenance lenalidomide (IDeM).	Yes	16/12/2020	1	88	69	01/05/2018	08/10/2020	07/11/2019	28/10/2020	09/10/2020	29/10/2020			
53	20/SC/0201	282769	ACCORD 2: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients	Yes	08/07/2020	12	57	69	29/04/2020	30/04/2020	28/04/2020	07/05/2020	12/05/2020	19/05/2020			
54	20/WA/0098	275346	Randomized, Open-Label, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Azacitidine Versus Best Supportive Care as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy	No		17			05/09/2019	12/10/2020	29/04/2020	06/10/2020	29/10/2020	30/10/2020			
55	20/EE/0101	281712	Randomised Evaluation of COVID-19 Therapy (RECOVERY)	Yes	06/04/2020	14	6	20	17/03/2020	17/03/2020	17/03/2020	13/03/2020	31/03/2020	31/03/2020			
56	20/ES/0122	1003500	Efficacy and Safety Assessment of T4030 Eye Drops versus Ganfort® UD in Ocular Hypertensive or Glaucomatous Patients	No					17/11/2020	17/12/2020	01/02/2021						
57	18/SC/0015	236685	A phase III, multicenter, randomized, double blind, placebo controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjunct therapy in adult subjects with stages AJCCUICC v. 8 I-IIA and IIB (T>4.5cm, N2) colorectal cancer (R01, gov, email)	Yes	19/04/2021	0	216	216	01/05/2019	15/09/2020	23/02/2018	02/09/2020	15/09/2020	28/09/2020			
58	19/EM/0299	265496	Real-time Remote Echo Mentoring	No		12			09/07/2019	27/02/2020	24/02/2020	20/08/2019	10/03/2020	10/03/2020			
59	20/HRA/1696	262238	Ventilation Strategies in COVID-19: CPAP, High-flow, and standard care	Yes	23/04/2020	11	3	14	08/04/2020	09/04/2020	03/04/2020	20/04/2020	20/04/2020	21/04/2020			
60	20/LO/1102	281671	RESPONSE - Breaking up prolonged sitting in people with type 2 diabetes: Optimising the response.	No					09/06/2020	21/12/2020	19/11/2020	07/01/2021					
61	20/NW/0381	1003380	A Randomised, Open-Label, Parallel-Group, Pre-surgical Study to Investigate the Biological Effects of AZD9833 in Women with ER-positive, HER2-negative Primary Breast Cancer	No					11/12/2020	21/12/2020	16/11/2020						
62	19/EM/0290	263656	A Pilot randomised controlled trial of the effects of a structured, home-based exercise program on Cardiovascular Structure and function in Renal Transplant recipients. The EC-SERT study	Yes	09/03/2020	9	39	48	15/04/2019	21/01/2020	14/10/2019	23/01/2020	30/01/2020	30/01/2020			
63	20/NW/0168	281317	A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFN-71a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection	Yes	06/04/2020	9	12	21	16/03/2020	16/03/2020	17/03/2020	24/03/2020	25/03/2020	25/03/2020			
64	20/YH/0317	288552	A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of A226.COVID.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older	Yes	25/11/2020	9	4	13	08/10/2020	12/11/2020	10/11/2020	20/11/2020	21/11/2020	21/11/2020			
65	18/LO/0660	237150	Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia	Yes	04/05/2020	5	6	11	07/04/2020	23/04/2020	23/07/2018	23/04/2020	28/04/2020	29/04/2020			
67	20/WM/0153	282437	The efficacy and feasibility of face mask sampling for hospitalised adult patients and healthcare workers with suspected COVID-19	No		5			12/05/2020	04/06/2020	02/06/2020	09/06/2020	09/06/2020	10/06/2020			
68	19/NE/0145	254931	FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma	No					05/02/2019	30/12/2020	22/07/2019	08/01/2021					
69	20/SC/0111	276734	DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab, Melphalan, Bortezomib, and Dexamethasone (B-Vd) Compared with the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants with Relapsed/Refractory Multiple Myeloma	Yes	23/11/2020	0	63	63	11/12/2019	21/09/2020	12/05/2020	08/09/2020	21/09/2020	22/09/2020			